Core Viewpoint - WuXi AppTec's CAR-T cell therapy, Rukiyoulan, is making progress in negotiations to be included in the commercial health insurance innovative drug directory, which is expected to reduce the financial burden on patients and benefit more individuals [1] Group 1: Stock Performance - WuXi AppTec-B (02126) saw its stock price increase by over 10%, trading at 3.82 HKD with a transaction volume of 4.6331 million HKD as of the report [1] Group 2: Product Development - Rukiyoulan, the first domestically approved Class 1 CAR-T therapy in China, has a listed price of 1.29 million RMB per injection [1] - The company announced a strategic cooperation supplementary agreement with Regeneron Pharmaceuticals on October 30, marking a significant upgrade in their long-term partnership and initiating a new phase in TCR-T cell therapy and platform technology innovation [1] Group 3: Financial Aspects - The supplementary agreement allows WuXi AppTec to receive up to 50 million USD in payments, which includes milestone payments for MAGE-A4 product development, drug manufacturing process supervision, option exercise fees, and milestone payments for lentiviral vector manufacturing processes [1]
港股异动 | 药明巨诺-B(02126)涨超10% 报道称其CAR-T药物有望进入商保目录